Order Article Reprints

Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G, Berardi R, Cardellino GG, De Manzoni G, De Vita F, et al. TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers. 2021; 13(11):2839. https://doi.org/10.3390/cancers13112839

Raimondi, Alessandra, Federica Palermo, Michele Prisciandaro, Massimo Aglietta, Lorenzo Antonuzzo, Giuseppe Aprile, Rossana Berardi, Giovanni G. Cardellino, Giovanni De Manzoni, Ferdinando De Vita, and et al. 2021. "TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study" Cancers 13, no. 11: 2839. https://doi.org/10.3390/cancers13112839

Raimondi, A., Palermo, F., Prisciandaro, M., Aglietta, M., Antonuzzo, L., Aprile, G., Berardi, R., Cardellino, G. G., De Manzoni, G., De Vita, F., Di Maio, M., Fornaro, L., Frassineti, G. L., Granetto, C., Iachetta, F., Lonardi, S., Murialdo, R., Ongaro, E., Pucci, F., ... Pietrantonio, F. (2021). TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers, 13(11), 2839. https://doi.org/10.3390/cancers13112839